Nearly half of advanced ovarian cancer patients relapsed after first-line PARP inhibitor maintenance, emphasizing the need for refined postrecurrence strategies. BRCA mutation carriers were more ...

An Ohio State University molecular biologist leveraged a supercomputer to help better define the family tree of a group of enzymes that have been implicated in a wide range of human diseases and are ...

In a recent issue of the Journal of Clinical Oncology Ramalingam et al. published the much-awaited results of their phase III trial evaluating the role of a PARP inhibitor in combination with ...

Maurie Markman, MD: How do PARP inhibitors impact the landscape of ovarian cancer treatment, from your perspective, as of today? Justin Chura, MD: When we’re talking about the recurrent setting and we ...

Ovarian cancer has a poor prognosis, mainly because it is usually at an advanced stage by the time it is detected. Today 90% of people with breast cancer will be cured, whereas 50% of those with ...

A study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP inhibitors.

The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval, making it the first precision medicine combo for patients with BRCA2-mutated metastatic ...